REFERENCES
- ANDREW E.: Adverse events in clinical research versus clin-ical routine. In: Patient safety and adverse events in con-trast medium examination, ch. 2. Edited by I. Enge and J. Edgren. Elsevier Science Publishers B.V. (Biomedical Divi-sion), Amsterdam 1989.
- CAR D. H., BROWN J. & BYDDER G. M.: Intravenous che-lated gadolinium as a contrast agent in NMR imaging of cerebral tumours. Lancet 3 (1984), 484.
- COHAN R. H., Ellis J. H. & GARNER W. L.: Extravasation of radiographic contrast material. Recognition, prevention and treatment. Radiology 200 (1996), 593.
- GOLDSTEIN H. A., KASHANIAN F. K., BLUMETTI R. F, Ho- 665 LYOAK W. L., HUGO E P. & BLUMENFIELD D. M.: Safety assessment of gadopentetate dimeglumine in U.S. clinical trials. Radiology 174 (1990), 17.
- KATAYAMA H., YAMAGUCHI K., KOZUKA T., TAKASHIMA T., SEEZ P. & MATSUURA K.: Adverse reactions to ionic and nonionic contrast media. Radiology 175 (1990), 621.
- LUNDBY B., SVALAND M., GORDON P, ASIANIAN V, JOHNS-SON E. & CATTON D.: Experience with gadodiamide injec-tion (Omniscan) in clinical phase III trials. Clin. MRI 5 (1995), 103.
- MURPHY K. J., BRUNBERG J. A. & COHAN R. H.: Adverse reactions to gadolinium contrast media. A review of 36 cases. AJR 167 (1996), 847.
- NELSON K. L., GIFFORD L. M., LAUBER-HUBER C., GROSS C. A. & LASSER T. A.: Clinical safety of gadopentetate di-meglumine. Radiology 196 (1995), 439.
- NIENDORF H. P, DINGER J. C., HAUSTEIN J., CORNELIUS I., ALHASSAN A. & CLAUSS W: Tolerance data of Gd-DTPA. A review. Eur. J. Radiol. 13 (1991), 15.
- RUNGE V. M., CAROLLO B. R., WOLF C. R., NELSON K. L. & GELBLUM D. Y: Gd-DTPA. A review of clinical indi-cations in central nervous system magnetic resonance im-aging. Radiographics 9 (1989), 929.
- SZE G.: New applications of MR contrast agents in neuro-radiology. Neuroradiology 32 (1990), 421.